Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027819 (
neuroblastoma
)
27,800
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
CYTL1
is a novel cytokine that was first identified in CD34
+
hematopoietic cells. We previously prepared recombinant
CYTL1
and verified that it chemoattracted human monocytes via the CCR2/ERK pathway. It has been reported that
CYTL1
plays contradictory roles in
neuroblastoma
and lung cancer. We found that the expression level of
CYTL1
was notably decreased and it was hypermethylated in various tumors, including breast and lung cancer, by bioinformatics analyses. After validating the expression of
CYTL1
in lung cancer, we identified that
CYTL1
exerted no obvious effect on tumor cell proliferation but inhibited their migration and invasion, and these effects were accompanied by decreasing STAT3 phosphorylation, using recombinant
CYTL1
and
CYTL1
-overexpressing tumor cell lines. Furthermore, we constructed experimental and spontaneous metastasis models of breast cancer in BALB/c mice and found that
CYTL1
significantly inhibited tumor metastasis
in vivo
. In summary,
CYTL1
is a cytokine with tumor-suppressing characteristics that inhibits tumor metastasis and STAT3 phosphorylation in multiple types of tumors.
...
PMID:CYTL1 inhibits tumor metastasis with decreasing STAT3 phosphorylation. 3106 37